KIT

GIST Research – Correlation of Target Kinase Genotype with Clinical Activity of Imatnib Mesylate in KIT Patients

GIST patients with a particular genetic mutation are more likely to respond to Gleevec than those without the mutation, reported Dr. Michael C. Heinrich at one of the plenary sessions of the annual conference of the American Society of Clinical Oncology, held May 14-17 in Orlando, Florida.

By |2018-07-08T19:05:45-04:00May 11th, 2007|Tissue Bank|

Looking for Kinase Mutations in GISTs

This is the second of a two-part series on KIT and PDGFRA mutations in GISTs, written collaboratively by Drs. Michael Heinrich and Christopher Corless, LRG research team members. Please refer to the May issue of our newsletter for the first part titled, “KIT & PDGFRA mutations in GIST: A to Z” by Dr. Heinrich.

By |2018-05-29T13:29:32-04:00May 11th, 2007|Mutational Testing, Mutations|
Go to Top